vTv Therapeutics (VTVT)
(Delayed Data from NSDQ)
$22.38 USD
+1.03 (4.83%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $22.97 +0.59 (2.64%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth B Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
VTVT 22.38 +1.03(4.83%)
Will VTVT be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for VTVT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VTVT
The Zacks Analyst Blog Highlights Sarepta Therapeutics, Incyte, Gilead Sciences and VTv Therapeutics
Biotech Stock Roundup: Patient Death Hits SRPT, INCY Study Data & More
VTVT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for VTVT
VTVT forms Pocket Pivot on September 19
VTVT's price rises by 1.52% on September 19, though its technical setup remains stable.
Is VTVT building bullish momentum? Slingshot Bullish shows up after sliding 0.69%
vTv Therapeutics trading resumes
vTv Therapeutics trading resumes